Reducing Cardiovascular Risk in Diabetes: Beyond Glycemic and Blood Pressure Control.
From: Primary Care and General Practice, Primary Care Clinical Sciences Building, University of Birmingham, Edgbaston, UK.
International journal of cardiology
- Publish Date: Jun 2006
- ISSN: 0167-5273
- Volume: 110
- Issue: 2
- Pages: 137-45
- Medium: Print
- Language: English
- Citation (JAMA): Hobbs F D Richard, et al. Reducing Cardiovascular Risk in Diabetes: Beyond Glycemic and Blood Pressure Control.. Int. J. Cardiol. Jun 2006;110:137-45
Abstract
Patients with diabetes mellitus have a much higher rate of cardiovascular disease (CVD) than the general population, and, in addition to glycaemia and hypertension, dyslipidemia has emerged as an important modifiable cardiovascular risk factor in these patients. In most patients with type 2 diabetes, the major features of dyslipidemia are increased triglyceride levels, decreased high-density lipoprotein cholesterol (HDL-C) levels, and changes in the composition and level of low-density lipoprotein cholesterol (LDL-C). Clinical trials evaluating both primary and secondary prevention of CVD demonstrate that lipid-lowering therapy results in a substantial reduction of cardiovascular risk in patients with type 2 diabetes. Low-density lipoprotein cholesterol is the first priority for treatment, with a statin in adequate dosage as the first choice for pharmacological therapy. The first statin trial conducted solely in patients with type 2 diabetes and no prior CVD demonstrated a 37% reduction in cardiovascular events in patients randomized to atorvastatin 10 mg compared with placebo. Additional trials that further address the benefits of lipid-lowering therapy in patients with diabetes are near completion, or are underway, and should provide important information about further attenuating risk in patients with diabetes.
Mesh Headings (Keywords): Antilipemic Agents, Cholesterol, HDL, Cholesterol, LDL, Coronary Disease, Diabetes Mellitus, Type 2, Dyslipidemias, Heptanoic Acids, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypertension, Models, Biological, Practice Guidelines as Topic, Pyrroles, Randomized Controlled Trials as Topic, Risk Factors, Triglycerides
Check for Full Text / PubMed Unique Identifier (PMID): 16289373
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.